Previous 10 | Next 10 |
2023-09-11 13:08:20 ET Summary Roivant, a biopharmaceutical firm, focuses on inflammation and immunology, especially VTAMA for dermatology, showing significant growth. With strong financials, clinical successes, and a $9.72B market cap, Roivant has consistently outperformed the S&...
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it completed the redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants...
2023-09-09 11:17:21 ET Roivant Sciences (NASDAQ: ROIV) stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since December 2021. It has roared back by more t...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-08-28 18:00:00 ET If you are looking for some high-octane growth stocks to add to your portfolio, you might want to follow in the footsteps of some of the most successful investors in the biotech sector. Baker Bros. Advisors, a hedge fund founded by billionaire brothers Julian and Feli...
BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants...
2023-08-14 20:20:21 ET Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Conference Call August 14, 2023 08:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matthew Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief In...
2023-08-14 07:27:35 ET Roivant Sciences press release ( NASDAQ: ROIV ): FQ1 GAAP EPS of -$0.38 misses by $0.07 . Revenue of $21.62M (+400.5% Y/Y) misses by $2.87M . Roivant reported its consolidated cash, cash equivalents and restricted cash of $1.4B at June 30...
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses First patient has been dosed in the TAHOE study, a global Phase 2 trial of RVT-3...
2023-08-13 08:02:00 ET More on Cisco, Deere, etc. Compare metrics for CSCO to DE, HD, SNDL, TGT, WMT Walmart: The Bottom Could Fall Out If Inflation Levels Continue To Fall Home Depot: Long-Term Winner, With Room To Run Target estimates lowered at Barclays ah...
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Company Name:
ROIV Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Website:
2024-06-02 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31...